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Dear Sir,
Pelizaeus-Merzbacher disease (PMD) is an X-linked 
disorder caused by abnormalities in the proteolipid protein 
(PLP) gene which has been mapped to the Xq22 region 
(Willard and Riordan, 1985). The gene contains 7 exons 
(Diehl et al., 1986). In 10-25% of the families analysed,
mutations have been identified in all exons, but pre­
dominantly in exons 3, 4 and 5 (Hudson et al., 1989; 
Kleindorfer et al., 1995). As yet, more than 30 different 
exonic mutations have been reported (for review Hodes et 
al, 1993; Seitelberger, 1995), but no correlation could be 
found between the nature of the mutation and the severity
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Fig. 1, Pedigree of the family. Symbols: +,VOR disinhibition; —, hyporeactive VOR, 0, not examined; x, mutation carrier.
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of the disease (Hodes et al., 1993). Duplication of the PLP 
gene is the cause in about 25-60% of the families, which 
indicates that PLP gene overdosage might be an important 
genetic abnormality in PMD (Smeets, 1995; Hodes and 
Dlouhy, 1996; Inoue et al., 1996).
In 1992, we reported disinhibition of the vestibulo- 
ocular reflex (VOR) in a PMD family (Huygen et a l, 
1992). All three obligate carriers exhibited VOR disinhibi­
tion, which was also found in one of the seven possible 
carriers, but in none of the three unaffected males (Fig. 1). 
We had reason to believe that a' similar finding in the two 
affected males was prohibited by their ocular motor 
dysfunction. We speculated that VOR disinhibition might 
be a discriminating feature between carriers and non­
carriers of PMD. Recently, a pathogenic mutation has been 
identified in exon 2 of the PLP gene in this family, leading 
to substitution of Phe31 for Val. This mutation has not been 
reported before. Other amino acid substitutions in exon 2 
are Pro14Leu (Trofatter et al., 1989; Hodes et al., 1995) 
and Thr42lle (Dlouhy et a l, 1993; Pratt et al.5 .1995); a 
single base (A or G at the third position of codon 55, Gin) 
synonymous polymorphism was described by Osaka et al. 
(1995).
31The segregation of the Phe Val mutation in our family 
(Fig. 1) showed that the mutation was not only present in 
the patients and the obligate carriers, but also in four out of 
the seven possible carriers.
One woman with VOR disinhibition did not carry the 
mutation, while three carriers of the mutation had normal 
VOR findings. The fourth earner of the mutation showed a 
hyporeactive VOR.
We conclude that molecular genetic analysis is neces­
sary for reliable carrier detection in PMD; VOR testing or 
MRI alone are not useful (Huygen et al., 1992; Hodes et 
al., 1995).
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